GSK's Witty calls for an R&D renaissance

GSK CEO Andrew Witty (photo) wants everyone to know that he gets it. R&D productivity in the industry is awful, industrializing the creative process failed. And now Big Pharma has to rely on partnering with biotechs and academics to get its mojo back, recognizing that this is as much art as science. Pharma companies, meanwhile, will have to do more deals like Viiv Healthcare, which pooled its HIV products and pipelines with Pfizer. That's Witty's bottom line in an editorial he wrote for the Economist. Column

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."